POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
26 Juni 2023 - 1:45PM
POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or
“POINT”), a company accelerating the discovery, development, and
global access to life-changing radiopharmaceuticals, and AdvanCell,
a company developing an innovative pipeline of targeted alpha
therapies with a platform technology to produce 212Pb
radiopharmaceuticals, today announced a collaboration on the
development of a global 212Pb radioisotope and radioligand supply
chain and drug manufacturing network to specifically support the
clinical development and commercialization of 212Pb-labeled
radioligands by each company.
212Pb is differentiated as both an alpha and
beta-emitting isotope with a simple decay chain that has
demonstrated promising clinical results1 in compassionate use and
phase 1 settings. 212Pb is produced via a generator using thorium
(228Th, 1.9 year half-life) or radium (224Ra, 3.6 day half-life)
sources. 228Th is available in significant quantities and has a
half-life that supports 212Pb generators with ~1 year shelf-lives
stationed at a selected number of regional locations globally. The
short half-life of 212Pb (10.6 hours) has the benefit of delivering
>99% of the tumor cell–killing radiation in only 72 hours, which
reduces the time that the ligand needs to be retained in the tumor,
a common limitation for targeted radioligand therapies. The short
half-life may also promote the earlier maintenance of functional
immune cells infiltrating the tumor relative to longer-lived
isotopes. In contrast, only ~20% of the decays from 225Ac occur in
72 hours, so prolonged tumor retention is required to achieve the
same payload delivery.
“We constantly strive to use the right isotope
for the job, and variations in ligand and tumor characteristics
require different isotope properties,” said Joe McCann, Ph.D.,
Chief Executive Officer of POINT Biopharma. “Adding 212Pb to our
toolbox increases the optionality for new programs with the goal of
developing new therapeutic options with improved clinical outcomes.
Importantly, AdvanCell’s proprietary 212Pb generator technology
based on 228Th sources is next-generation technology that we
believe can scale to commercial quantities. Having a greater range
of isotope choices, combined with supply chain visibility and
control over access, will facilitate not only robust clinical
development programs but also make eventual supply for
commercialization more predictable as we look to expand our
pipeline to bring next-generation radioligands to more
patients.”
“AdvanCell is delighted to collaborate with
POINT Biopharma, whose excellence and track record in manufacturing
and clinical development we have admired and respected for some
time,” said Andrew Adamovich, Chief Executive Officer of AdvanCell.
“AdvanCell was founded on the belief that targeted alpha therapies
will change the course of cancer treatment. These treatments have
demonstrated incredible efficacy but have been hampered by
manufacturing and supply issues. AdvanCell’s technology, in
combination with POINT’s demonstrated manufacturing expertise and
our joint commitment to developing life-saving therapies, will
deliver on the promise of targeted alpha therapy and positively
impact the lives of many. As AdvanCell progresses ADVC001, our lead
clinical program for the treatment of metastatic prostate cancer,
this collaboration will accelerate clinical development and ensure
the scaled supply of these important medicines.”
Terms were not disclosed.
[1] Delpassand et al. J Nucl Med. 2022
Sep;63(9):1326-1333.
About POINT
BiopharmaPOINT Biopharma Global Inc. is a globally focused
radiopharmaceutical company building a platform for the clinical
development and commercialization of radioligands that fight
cancer. POINT aims to transform precision oncology by combining a
portfolio of targeted radioligand assets, a seasoned management
team, an industry-leading pipeline, in-house manufacturing
capabilities, and secured supply for medical isotopes including
actinium-225 and lutetium-177. POINT’s active clinical trials
include FRONTIER, a phase 1 trial for PNT2004, a pan-cancer program
targeting fibroblast activation protein-α (FAP-α), and SPLASH, the
phase 3 trial for PNT2002 for people with metastatic castration
resistant prostate cancer (mCRPC) after second-line hormonal
treatment. Learn more about POINT Biopharma Global Inc.
at https://www.pointbiopharma.com/.
About
AdvanCell
AdvanCell is a
radiopharmaceutical company developing an innovative pipeline of
targeted alpha therapies to improve clinical outcomes in cancer
patients. AdvanCell’s Targeted Alpha Therapies are powered by a
proprietary platform technology – a novel alpha isotope generator
that addresses the greatest unmet need in Targeted Alpha Therapy –
the reliable and scalable supply of isotope. For more information,
visit www.advancell.com.au
Forward
Looking StatementsThis press release contains
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
In some cases, you can identify forward-looking statements by the
following words: “may,” “will,” “could,” “would,” “should,”
“expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “ongoing” or the
negative of these terms or other comparable terminology, although
not all forward-looking statements contain these words. These
statements involve risks, uncertainties and other factors that may
cause actual results, levels of activity, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Although
we believe that we have a reasonable basis for each forward-looking
statement contained in this press release, we caution you that
these statements are based on a combination of facts and factors
currently known by us and our projections of the future, about
which we cannot be certain. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the benefits of the recently completed business combination, as
well as statements about the potential attributes and benefits of
POINT’s product candidates and the format and timing of POINT’s
product development activities and clinical trials. We cannot
assure you that the forward-looking statements in this press
release will prove to be accurate. These forward-looking statements
are subject to a number of significant risks and uncertainties that
could cause actual results to differ materially from expected
results, including, among others, our ability to grow and manage
our growth profitably and retain our key employees, the impact of
COVID-19 on our business, the success, cost and timing of our
product development activities and clinical trials, our ability to
obtain and maintain regulatory approval for our product candidates,
our ability to obtain funding for our operations, our the ability
to maintain the listing of our common stock on the NASDAQ, changes
in applicable laws or regulations, the possibility that POINT may
be adversely affected by other economic, business, and/or
competitive factors, and other risks and uncertainties, including
those described in our Annual Report on Form 10-K filed with the
SEC on March 27, 2023. Many of these factors are outside of POINT’s
control and are difficult to predict. Furthermore, if the
forward-looking statements prove to be inaccurate, the inaccuracy
may be material. In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by us or any other person that we
will achieve our objectives and plans in any specified time frame,
or at all. The forward-looking statements in this press release
represent our views as of the date of this press release. We
anticipate that subsequent events and developments will cause our
views to change. However, while we may elect to update these
forward-looking statements at some point in the future, we have no
current intention of doing so except to the extent required by
applicable law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.Investor
Relations Contact:Daniel PearlsteinDirector,
Strategyinvestors@pointbiopharma.com
AdvanCell
Contact:contact@advancell.com.au
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024